Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT06459245 Enrolling by invitation - Clinical trials for Breast Cancer Female

Resistance Training to Prevent Lymphedema After Breast Cancer Surgery Randomized Controlled Study

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

Based on the best evidence, this study intends to construct resistance appropriate for this clinical scenario,The training program was designed in a randomized controlled study for patients with breast cancer after surgery for a period of 3 months,To investigate the effect of resistance training on the grip strength of the affected limb, the range of motion of the shoulder joint of the affected limb, the occurrence of lymphedema of the affected limb, and the quality of life of patients with breast cancer after surgery,To provide theoretical guidance and practical basis for functional rehabilitation management of patients with affected limbs after surgery.

NCT ID: NCT06458764 Recruiting - Clinical trials for Breast Cancer Female

Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study

SEXCHECK
Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

Primary objectives: - To estimate Sexual Dysfunction (SD) incidence in premenopausal breast cancer patients treated by surgery and taking endocrine therapy. - To detect the presence of SD-related distress in the population, as a determining factor in the maintenance of a good quality of life. Secondary objectives: - To describe SD characteristics determining the most frequently reported symptoms and correlations with type of surgery or therapeutic regimens. - Collect baseline data for subsequent randomized trials involving practical interventions with the aim to reduce SD prevalence in this population.

NCT ID: NCT06458413 Recruiting - Clinical trials for Breast Cancer Recurrent

Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Start date: June 5, 2024
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients. This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.

NCT ID: NCT06457282 Not yet recruiting - Breast Cancer Clinical Trials

Studying The Association Between Environmental Exposure to PFAS and Breast Cancer in Assiut Governorate- Egypt

Start date: July 2024
Phase:
Study type: Observational

1. Measuring serum level of PFAS in breast cancer female patients and healthy participants. 2. Studying the correlation between serum level of PFAS and breast cancer risk through statistical modeling and analysis. 3. Studying the magnitude of environmental exposure through measuring levels of PFAS in air and water sources of corresponding participants.

NCT ID: NCT06456411 Recruiting - Breast Carcinoma Clinical Trials

Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer

Start date: July 12, 2022
Phase:
Study type: Observational

This clinical trial attempts to measure pain severity, location of pain, and feasibility in patients with cancer using functional near-infrared spectroscopy and virtual reality relaxation programs. Functional near-infrared spectroscopy and virtual reality relaxation programs may help relieve pain in patients with cancer who are receiving treatment.

NCT ID: NCT06455904 Recruiting - Breast Cancer Clinical Trials

Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study

PROTECT-07
Start date: May 30, 2024
Phase: N/A
Study type: Interventional

The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.

NCT ID: NCT06455657 Recruiting - Breast Cancer Clinical Trials

Breast Cancer Education to Prisoner Women

Start date: May 24, 2024
Phase: N/A
Study type: Interventional

The aim of the study is to determine the effect of breast cancer education given to incarcerated women on breast cancer knowledge and awareness.

NCT ID: NCT06454864 Not yet recruiting - Clinical trials for Breast Cancer Female

Multiple Risk Factor Intervention Trial in Breast Cancer Survivors

MsFITBC
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

This study aims to produce new evidence on the efficacy of exercise and diet for cardiometabolic risk reduction in BC survivors. Using a 3-arm RCT with to 6 months of 1) exercise following Health Canada guidelines; 2) the same exercise plus counselling to follow Canada's Dietary Guidelines to improve diet quality; or 3) stretching group, this study will answer the following questions: - What is the impact of exercise on cardiometabolic health and body composition in BC survivors? - What is the effect modification of adding a diet quality intervention to exercise on cardiometabolic health and body composition? - Is there a link between the capacity of skeletal muscle adaptation to exercise (and diet) and insulin resistance in BC survivors? The investigators hypothesize that: 1) exercise will improve cardiometabolic and body composition outcomes 2) improvements in cardiometabolic outcomes will be enhanced by the addition of diet quality, which will be essential or additive for Matsuda index, metabolic syndrome, Framingham CVD risk, thigh myosteatosis, muscle mass, VO2peak, 3) skeletal muscle insulin signalling transduction will be impaired in BC survivors via dampened expression of insulin-responsive proteins (e.g. GLUT4) and co-occur with impaired muscle quality (e.g., higher rates of fat depots, presence of fibrous tissue) negatively impacting insulin signalling.

NCT ID: NCT06452706 Not yet recruiting - Breast Cancer Clinical Trials

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.

NCT ID: NCT06452485 Recruiting - Breast Cancer Clinical Trials

Postoperative Re-irradiaTion With and Without HYPERthermia: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer

RT-HYPE
Start date: January 1, 2024
Phase:
Study type: Observational

In the Netherlands, breast cancer patients with locoregional recurrence (LRR) and high-risk factors are treated with postoperative re-irradiation with or without hyperthermia. Retrospective studies showed that 3-year locoregional control after postoperative re-irradiation with hyperthermia was 68-83%, and severe toxicity in up to 40% of LRR patients. Unfortunately, no prospective (randomized) data are available on clinical outcomes. Consequently, variation exists in hyperthermia-treatment and re-irradiation schedules. Prospective real-world data on oncological outcomes, toxicity and quality of life is highly needed for shared decision-making between patients and professionals. These data will be used in the design of a future randomized trial comparing postoperative re-irradiation and hyperthermia-treatment in high-risk LRR patients.